Target intelligence / Profile preview

Calcium-activated chloride channel protein (most often referring to the prototypical TMEM16A protein, also called Anoctamin-1) (TMEM16A (anoctamin-1, ANO1); sometimes CaCC for the channel class)

Target
TMEM16A (anoctamin-1, ANO1); sometimes CaCC for the channel class
Molecular classification
Ion channel, Ligand-gated ion channel, TMEM16 family, Anoctamin, Membrane protein
01

Overview

The **calcium-activated chloride channel protein** most commonly refers to **TMEM16A (anoctamin-1, ANO1)**, a ligand-gated ion channel that conducts chloride ions across cell membranes in response to intracellular calcium. TMEM16A is the prototypical member of the TMEM16/anoctamin family, consisting of 10 transmembrane domains and activated by increases in cytosolic Ca²⁺. These channels are broadly expressed in epithelial, endothelial, smooth muscle, and some neuronal cells. Their principal biological roles include regulation of epithelial fluid secretion, control of smooth muscle contraction, and mediation of sensory perception. TMEM16A is implicated as a therapeutic target in diverse diseases including cystic fibrosis (where it may compensate for CFTR dysfunction), cancer (with overexpression in various tumors), hypertension, fibrosis, and some neurological conditions. Several drugs and small molecule inhibitors—such as CaCCinh-A01, T16Ainh-A01, and Ani9—act on TMEM16A by blocking the ion conduction pore or by promoting protein degradation. The channel is also known as DOG1 in the context of GI stromal tumor diagnostics. Despite its therapeutic potential, the ubiquity of TMEM16A requires careful strategies to avoid unwanted systemic effects, especially when targeting diseases that involve secretory epithelia or smooth muscle[1][2][4][6][7][8].

Other names
Calcium-activated chloride channelCaCCTMEM16AAnoctamin-1ANO1Discovered on gastrointestinal stromal tumors 1 (DOG1)Calcium-dependent chloride channelTMEM16 family proteinChloride channel accessory protein (CLCA)Bestrophin
02

Mechanism of action

Inhibition of chloride currents (reducing secretion or excitability); Allosteric modulation of channel (pore and non-pore site binding for inhibitors); Modulation of calcium sensitivity and gating; Indirect action via protein depletion/degradation (some inhibitors)

03

Biological functions

Epithelial and endothelial ion/fluid secretionSensory signal transductionSmooth muscle contraction and excitabilityPacemaker activity (e.g., in gut through interstitial cells of Cajal)Regulation of mucus productionProliferation and migration in some cell types
04

Disease associations

Cystic fibrosisHypertensionCancer (various solid tumors: GI stromal tumors, colon, lung, breast, prostate, glioblastoma)StrokeFibrosis (e.g., kidney fibrogenesis)Respiratory diseases (e.g., asthma, chronic obstructive pulmonary disease)ConstipationOsteoporosisPotential role in COVID-19 (as a druggable pathway for symptoms/sequelae)
05

Safety considerations

Widespread physiological expression (risk of off-target effects, e.g., in epithelia, vascular smooth muscle, neurons)Alteration of fluid/electrolyte balance (potential dehydration, impaired mucosal function)Cardiovascular side effects (if vascular tone is affected)Unintended impact on sensory transduction or gut motility
06

Interacting drugs

CaCCinh-A01 (inhibitor)

8 more in the full profile.

07

Biomarkers

DOG1/ANO1 (diagnostic marker in gastrointestinal stromal tumors)Expression level in tumors (for prognosis/patient selection in cancer)

Beyond the preview

Go deeper on Calcium-activated chloride channel protein (most often referring to the prototypical TMEM16A protein, also called Anoctamin-1) (TMEM16A (anoctamin-1, ANO1); sometimes CaCC for the channel class).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Calcium-activated chloride channel protein (most often referring to the prototypical TMEM16A protein, also called Anoctamin-1) (TMEM16A (anoctamin-1, ANO1); sometimes CaCC for the channel class).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call